{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:36:50Z","timestamp":1792460210832,"version":"4.5.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81822016"],"award-info":[{"award-number":["No. 81822016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81771382"],"award-info":[{"award-number":["No.81771382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No. 2018CFA036"],"award-info":[{"award-number":["No. 2018CFA036"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12035-020-02232-6","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T01:04:15Z","timestamp":1609981455000},"page":"2183-2201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":196,"title":["Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets"],"prefix":"10.1007","volume":"58","author":[{"given":"Lijun","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifen","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-1472","authenticated-orcid":false,"given":"Zhentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"2232_CR1","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","volume":"45","author":"JM Dietschy","year":"2004","unstructured":"Dietschy JM, Turley SD (2004) Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45:1375\u20131397. https:\/\/doi.org\/10.1194\/jlr.R400004-JLR200","journal-title":"J Lipid Res"},{"key":"2232_CR2","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1242\/dmm.010124","volume":"5","author":"JE Vance","year":"2012","unstructured":"Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech 5:746\u2013755. https:\/\/doi.org\/10.1242\/dmm.010124","journal-title":"Dis Model Mech"},{"key":"2232_CR3","volume-title":"Biochemistry","author":"JM Berg","year":"2002","unstructured":"Berg JM, Tymoczko JL, Stryer L (2002) The complex regulation of cholesterol biosynthesis takes place at several levels. In: Biochemistry, 5th edn. W.H. Freeman, New York","edition":"5"},{"key":"2232_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2009.05917.x","volume":"109","author":"K Nieweg","year":"2009","unstructured":"Nieweg K, Schaller H, Pfrieger FW (2009) Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 109:125\u2013134. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.05917.x","journal-title":"J Neurochem"},{"key":"2232_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nn1426","volume":"8","author":"G Saher","year":"2005","unstructured":"Saher G, Br\u00fcgger B, Lappe-Siefke C et al (2005) High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8:468\u2013475. https:\/\/doi.org\/10.1038\/nn1426","journal-title":"Nat Neurosci"},{"key":"2232_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.devbrainres.2003.09.015","volume":"146","author":"G Quan","year":"2003","unstructured":"Quan G, Xie C, Dietschy JM, Turley SD (2003) Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res Dev Brain Res 146:87\u201398. https:\/\/doi.org\/10.1016\/j.devbrainres.2003.09.015","journal-title":"Brain Res Dev Brain Res"},{"key":"2232_CR7","doi-asserted-by":"publisher","first-page":"14256","DOI":"10.1016\/S0021-9258(19)45374-X","volume":"257","author":"RF DeGrella","year":"1982","unstructured":"DeGrella RF, Simoni RD (1982) Intracellular transport of cholesterol to the plasma membrane. J Biol Chem 257:14256\u201314262","journal-title":"J Biol Chem"},{"key":"2232_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1083\/jcb.101.2.446","volume":"101","author":"MR Kaplan","year":"1985","unstructured":"Kaplan MR, Simoni RD (1985) Transport of cholesterol from the endoplasmic reticulum to the plasma membrane. J Cell Biol 101:446\u2013453. https:\/\/doi.org\/10.1083\/jcb.101.2.446","journal-title":"J Cell Biol"},{"key":"2232_CR9","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1073\/pnas.140218797","volume":"97","author":"S Heino","year":"2000","unstructured":"Heino S, Lusa S, Somerharju P et al (2000) Dissecting the role of the Golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell surface. Proc Natl Acad Sci 97:8375\u20138380. https:\/\/doi.org\/10.1073\/pnas.140218797","journal-title":"Proc Natl Acad Sci"},{"key":"2232_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbalip.2014.12.018","volume":"1851","author":"V Leoni","year":"2015","unstructured":"Leoni V, Caccia C (2015) The impairment of cholesterol metabolism in Huntington disease. Biochim Biophys Acta 1851:1095\u20131105. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.018","journal-title":"Biochim Biophys Acta"},{"key":"2232_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fphys.2012.00486","volume":"3","author":"L Anchisi","year":"2013","unstructured":"Anchisi L, Dess\u00ec S, Pani A, Mandas A (2013) Cholesterol homeostasis: a key to prevent or slow down neurodegeneration. Front Physiol 3:486. https:\/\/doi.org\/10.3389\/fphys.2012.00486","journal-title":"Front Physiol"},{"key":"2232_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.15252\/emmm.201303711","volume":"6","author":"MG Martin","year":"2014","unstructured":"Martin MG, Ahmed T, Korovaichuk A et al (2014) Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents. EMBO Mol Med 6:902\u2013917. https:\/\/doi.org\/10.15252\/emmm.201303711","journal-title":"EMBO Mol Med"},{"key":"2232_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1471-4159.2007.05099.x","volume":"104","author":"WS Kim","year":"2008","unstructured":"Kim WS, Weickert CS, Garner B (2008) Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 104:1145\u20131166. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05099.x","journal-title":"J Neurochem"},{"key":"2232_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MOL.0b013e32832d3a10","volume":"20","author":"J Herz","year":"2009","unstructured":"Herz J (2009) Apolipoprotein E receptors in the nervous system. Curr Opin Lipidol 20:190\u2013196. https:\/\/doi.org\/10.1097\/MOL.0b013e32832d3a10","journal-title":"Curr Opin Lipidol"},{"key":"2232_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/mp.2012.15","volume":"17","author":"C Pottier","year":"2012","unstructured":"Pottier C, Hannequin D, Coutant S et al (2012) High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 17:875\u2013879. https:\/\/doi.org\/10.1038\/mp.2012.15","journal-title":"Mol Psychiatry"},{"key":"2232_CR16","doi-asserted-by":"publisher","first-page":"8935","DOI":"10.1074\/jbc.M112.400358","volume":"288","author":"JV Rushworth","year":"2013","unstructured":"Rushworth JV, Griffiths HH, Watt NT, Hooper NM (2013) Prion protein-mediated toxicity of amyloid-\u03b2 oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem 288:8935\u20138951. https:\/\/doi.org\/10.1074\/jbc.M112.400358","journal-title":"J Biol Chem"},{"key":"2232_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0021-9150(00)81081-3","volume":"151","author":"P Rensen","year":"2000","unstructured":"Rensen P, Jong MC, Vark LC et al (2000) Internalization of apolipoprotein E by hepatocytes via the LDL receptor is coupled to retroendocytosis. Atherosclerosis 151:239. https:\/\/doi.org\/10.1016\/S0021-9150(00)81081-3","journal-title":"Atherosclerosis"},{"key":"2232_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1194\/jlr.R047837","volume":"55","author":"JE Vance","year":"2014","unstructured":"Vance JE, Karten B (2014) Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin. J Lipid Res 55:1609\u20131621. https:\/\/doi.org\/10.1194\/jlr.R047837","journal-title":"J Lipid Res"},{"key":"2232_CR19","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1073\/pnas.0913828107","volume":"107","author":"EY Bryleva","year":"2010","unstructured":"Bryleva EY, Rogers MA, Chang CCY et al (2010) ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci 107:3081\u20133086. https:\/\/doi.org\/10.1073\/pnas.0913828107","journal-title":"Proc Natl Acad Sci"},{"key":"2232_CR20","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1073\/pnas.0810895106","volume":"106","author":"B Liu","year":"2009","unstructured":"Liu B, Turley SD, Burns DK et al (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-\/- mouse. Proc Natl Acad Sci 106:2377\u20132382. https:\/\/doi.org\/10.1073\/pnas.0810895106","journal-title":"Proc Natl Acad Sci"},{"key":"2232_CR21","doi-asserted-by":"publisher","first-page":"42781","DOI":"10.1074\/jbc.M207601200","volume":"277","author":"U Panzenboeck","year":"2002","unstructured":"Panzenboeck U et al (2002) ABCA1 and SR-BI are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem 277:42781\u201342789","journal-title":"J Biol Chem"},{"key":"2232_CR22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0022-2275(20)39867-9","volume":"36","author":"Y Lange","year":"1995","unstructured":"Lange Y, Ye J, Strebel F (1995) Movement of 25-hydroxycholesterol from the plasma membrane to the rough endoplasmic reticulum in cultured hepatoma cells. J Lipid Res 36:1092\u20131097","journal-title":"J Lipid Res"},{"key":"2232_CR23","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M200293-JLR200","volume":"43","author":"S Meaney","year":"2002","unstructured":"Meaney S, Bodin K, Diczfalusy U, Bj\u00f6rkhem I (2002) On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res 43:2130\u20132135. https:\/\/doi.org\/10.1194\/jlr.M200293-JLR200","journal-title":"J Lipid Res"},{"key":"2232_CR24","doi-asserted-by":"publisher","first-page":"22980","DOI":"10.1074\/jbc.M303415200","volume":"278","author":"EG Lund","year":"2003","unstructured":"Lund EG, Xie C, Kotti T et al (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278:22980\u201322988. https:\/\/doi.org\/10.1074\/jbc.M303415200","journal-title":"J Biol Chem"},{"issue":"5","key":"2232_CR25","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/cne.21605","volume":"507","author":"DMO Ramirez","year":"2010","unstructured":"Ramirez DMO, Andersson S, Russell DW (2010) Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol 507(5):1676\u20131693","journal-title":"J Comp Neurol"},{"key":"2232_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1126\/science.1132814","volume":"314","author":"M Goedert","year":"2006","unstructured":"Goedert M, Spillantini MG (2006) A century of Alzheimer\u2019s disease. Science 314:777\u2013781. https:\/\/doi.org\/10.1126\/science.1132814","journal-title":"Science"},{"key":"2232_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1600-0404.2006.00685.x","volume":"185","author":"M Kivipelto","year":"2006","unstructured":"Kivipelto M, Solomon A (2006) Cholesterol as a risk factor for Alzheimer\u2019s disease - epidemiological evidence. Acta Neurol Scand Suppl 185:50\u201357. https:\/\/doi.org\/10.1111\/j.1600-0404.2006.00685.x","journal-title":"Acta Neurol Scand Suppl"},{"key":"2232_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1212\/01.wnl.0000256368.57375.b7","volume":"68","author":"A Solomon","year":"2007","unstructured":"Solomon A, K\u00e5reholt I, Ngandu T et al (2007) Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68:751\u2013756. https:\/\/doi.org\/10.1212\/01.wnl.0000256368.57375.b7","journal-title":"Neurology"},{"key":"2232_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","volume":"71","author":"B Reed","year":"2014","unstructured":"Reed B, Villeneuve S, Mack W et al (2014) Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 71:195. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5390","journal-title":"JAMA Neurol"},{"key":"2232_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcp.2012.12.007","volume":"86","author":"J Popp","year":"2013","unstructured":"Popp J, Meichsner S, K\u00f6lsch H et al (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer\u2019s disease. Biochem Pharmacol 86:37\u201342. https:\/\/doi.org\/10.1016\/j.bcp.2012.12.007","journal-title":"Biochem Pharmacol"},{"key":"2232_CR31","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/archneur.62.10.1556","volume":"62","author":"M Kivipelto","year":"2005","unstructured":"Kivipelto M, Ngandu T, Fratiglioni L et al (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62:1556\u20131560. https:\/\/doi.org\/10.1001\/archneur.62.10.1556","journal-title":"Arch Neurol"},{"key":"2232_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1006\/bbrc.1998.9652","volume":"252","author":"YM Kuo","year":"1998","unstructured":"Kuo YM, Emmerling MR, Bisgaier CL et al (1998) Elevated low-density lipoprotein in Alzheimer\u2019s disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252:711\u2013715. https:\/\/doi.org\/10.1006\/bbrc.1998.9652","journal-title":"Biochem Biophys Res Commun"},{"key":"2232_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1471-4159.2012.07893.x","volume":"123","author":"J Popp","year":"2012","unstructured":"Popp J, Lewczuk P, K\u00f6lsch H et al (2012) Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer\u2019s disease. J Neurochem 123:310\u2013316. https:\/\/doi.org\/10.1111\/j.1471-4159.2012.07893.x","journal-title":"J Neurochem"},{"key":"2232_CR34","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000115847","volume":"25","author":"C Reitz","year":"2008","unstructured":"Reitz C, Tang M-X, Manly J et al (2008) Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 25:232\u2013237. https:\/\/doi.org\/10.1159\/000115847","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2232_CR35","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1212\/01.WNL.0000161870.78572.A5","volume":"64","author":"MM Mielke","year":"2005","unstructured":"Mielke MM, Zandi PP, Sj\u00f6gren M et al (2005) High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64:1689\u20131695. https:\/\/doi.org\/10.1212\/01.WNL.0000161870.78572.A5","journal-title":"Neurology"},{"key":"2232_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/JAD-160826","volume":"56","author":"KJ Anstey","year":"2017","unstructured":"Anstey KJ, Ashby-Mitchell K, Peters R (2017) Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis 56:215\u2013228. https:\/\/doi.org\/10.3233\/JAD-160826","journal-title":"J Alzheimers Dis"},{"key":"2232_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1194\/jlr.M300320-JLR200","volume":"45","author":"M Heverin","year":"2004","unstructured":"Heverin M, Bogdanovic N, L\u00fctjohann D et al (2004) Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer\u2019s disease. J Lipid Res 45:186\u2013193. https:\/\/doi.org\/10.1194\/jlr.M300320-JLR200","journal-title":"J Lipid Res"},{"key":"2232_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0197-4580(92)90116-f","volume":"13","author":"RP Mason","year":"1992","unstructured":"Mason RP, Shoemaker WJ, Shajenko L et al (1992) Evidence for changes in the Alzheimer\u2019s disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 13:413\u2013419. https:\/\/doi.org\/10.1016\/0197-4580(92)90116-f","journal-title":"Neurobiol Aging"},{"key":"2232_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1749-6632.1997.tb48466.x","volume":"826","author":"DL Sparks","year":"1997","unstructured":"Sparks DL (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer\u2019s disease? Ann N Y Acad Sci 826:128\u2013146. https:\/\/doi.org\/10.1111\/j.1749-6632.1997.tb48466.x","journal-title":"Ann N Y Acad Sci"},{"key":"2232_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000017234","volume":"11","author":"GP Eckert","year":"2000","unstructured":"Eckert GP, Cairns NJ, Maras A et al (2000) Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 11:181\u2013186. https:\/\/doi.org\/10.1159\/000017234","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2232_CR41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.nbd.2007.10.005","volume":"29","author":"H Xiong","year":"2008","unstructured":"Xiong H, Callaghan D, Jones A et al (2008) Cholesterol retention in Alzheimer\u2019s brain is responsible for high \u03b2- and \u03b3-secretase activities and A\u03b2 production. Neurobiol Dis 29:422\u2013437. https:\/\/doi.org\/10.1016\/j.nbd.2007.10.005","journal-title":"Neurobiol Dis"},{"key":"2232_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0022-3956(01)00050-4","volume":"36","author":"A Papassotiropoulos","year":"2002","unstructured":"Papassotiropoulos A, L\u00fctjohann D, Bagli M et al (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36:27\u201332. https:\/\/doi.org\/10.1016\/s0022-3956(01)00050-4","journal-title":"J Psychiatr Res"},{"key":"2232_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.redox.2016.09.001","volume":"10","author":"G Testa","year":"2016","unstructured":"Testa G, Staurenghi E, Zerbinati C et al (2016) Changes in brain oxysterols at different stages of Alzheimer\u2019s disease: their involvement in neuroinflammation. Redox Biol 10:24\u201333. https:\/\/doi.org\/10.1016\/j.redox.2016.09.001","journal-title":"Redox Biol"},{"key":"2232_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13024-019-0353-1","volume":"14","author":"A Yu","year":"2019","unstructured":"Yu A, Zhang X, Wang Y et al (2019) Longitudinal and nonlinear relations of dietary and serum cholesterol in midlife with cognitive decline: results from EMCOA study. Mol Neurodegener 14:51. https:\/\/doi.org\/10.1186\/s13024-019-0353-1","journal-title":"Mol Neurodegener"},{"key":"2232_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1212\/01.WNL.0000149519.47454.F2","volume":"64","author":"RA Whitmer","year":"2005","unstructured":"Whitmer RA, Sidney S, Selby J et al (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64:277\u2013281. https:\/\/doi.org\/10.1212\/01.WNL.0000149519.47454.F2","journal-title":"Neurology"},{"issue":"Suppl 2","key":"2232_CR46","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1055\/s-2003-43058","volume":"36","author":"C Kirsch","year":"2003","unstructured":"Kirsch C, Eckert GP, Koudinov AR, M\u00fcller WE (2003) Brain cholesterol, statins and Alzheimer\u2019s disease. Pharmacopsychiatry 36(Suppl 2):S113\u2013S119. https:\/\/doi.org\/10.1055\/s-2003-43058","journal-title":"Pharmacopsychiatry"},{"key":"2232_CR47","doi-asserted-by":"publisher","first-page":"67808","DOI":"10.18632\/oncotarget.12179","volume":"7","author":"P Th\u00e9riault","year":"2016","unstructured":"Th\u00e9riault P, ElAli A, Rivest S (2016) High fat diet exacerbates Alzheimer\u2019s disease-related pathology in APPswe\/PS1 mice. Oncotarget 7:67808\u201367827. https:\/\/doi.org\/10.18632\/oncotarget.12179","journal-title":"Oncotarget"},{"key":"2232_CR48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbr.2016.06.012","volume":"312","author":"A Ledreux","year":"2016","unstructured":"Ledreux A, Wang X, Schultzberg M et al (2016) Detrimental effects of a high fat\/high cholesterol diet on memory and hippocampal markers in aged rats. Behav Brain Res 312:294\u2013304. https:\/\/doi.org\/10.1016\/j.bbr.2016.06.012","journal-title":"Behav Brain Res"},{"key":"2232_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nbd.2017.01.004","volume":"100","author":"JM Walker","year":"2017","unstructured":"Walker JM, Dixit S, Saulsberry AC et al (2017) Reversal of high fat diet-induced obesity improves glucose tolerance, inflammatory response, \u03b2-amyloid accumulation and cognitive decline in the APP\/PSEN1 mouse model of Alzheimer\u2019s disease. Neurobiol Dis 100:87\u201398. https:\/\/doi.org\/10.1016\/j.nbd.2017.01.004","journal-title":"Neurobiol Dis"},{"key":"2232_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jalz.2018.10.001","volume":"15","author":"J Lehtisalo","year":"2019","unstructured":"Lehtisalo J, Lev\u00e4lahti E, Lindstr\u00f6m J et al (2019) Dietary changes and cognition over 2 years within a multidomain intervention trial\u2014the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimers Dement 15:410\u2013417. https:\/\/doi.org\/10.1016\/j.jalz.2018.10.001","journal-title":"Alzheimers Dement"},{"key":"2232_CR51","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A et al (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385:2255\u20132263. https:\/\/doi.org\/10.1016\/S0140-6736(15)60461-5","journal-title":"Lancet"},{"key":"2232_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2017.09.006","volume":"14","author":"A Rosenberg","year":"2018","unstructured":"Rosenberg A, Ngandu T, Rusanen M et al (2018) Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FINGER trial. Alzheimers Dement J Alzheimers Assoc 14:263\u2013270. https:\/\/doi.org\/10.1016\/j.jalz.2017.09.006","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2232_CR53","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00018-003-3018-7","volume":"60","author":"FW Pfrieger","year":"2003","unstructured":"Pfrieger FW (2003) Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci CMLS 60:1158\u20131171. https:\/\/doi.org\/10.1007\/s00018-003-3018-7","journal-title":"Cell Mol Life Sci CMLS"},{"key":"2232_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1385\/MN:31:1-3:185","volume":"31","author":"WG Wood","year":"2005","unstructured":"Wood WG, Igbavboa U, Eckert GP et al (2005) Is hypercholesterolemia a risk factor for Alzheimer\u2019s disease? Mol Neurobiol 31:185\u2013192. https:\/\/doi.org\/10.1385\/MN:31:1-3:185","journal-title":"Mol Neurobiol"},{"key":"2232_CR55","first-page":"4","volume":"20","author":"S Sonnino","year":"2013","unstructured":"Sonnino S, Prinetti A (2013) Membrane domains and the \u201clipid raft\u201d concept. Curr Med Chem 20:4\u201321","journal-title":"Curr Med Chem"},{"key":"2232_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00001756-200203250-00004","volume":"13","author":"H Hayashi","year":"2002","unstructured":"Hayashi H, Igbavboa U, Hamanaka H et al (2002) Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13:383\u2013386. https:\/\/doi.org\/10.1097\/00001756-200203250-00004","journal-title":"Neuroreport"},{"key":"2232_CR57","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1046\/j.1471-4159.1996.66041717.x","volume":"66","author":"U Igbavboa","year":"1996","unstructured":"Igbavboa U, Avdulov NA, Schroeder F, Wood WG (1996) Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem 66:1717\u20131725. https:\/\/doi.org\/10.1046\/j.1471-4159.1996.66041717.x","journal-title":"J Neurochem"},{"key":"2232_CR58","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1385\/nmm:8:3:319","volume":"8","author":"MP Burns","year":"2006","unstructured":"Burns MP, Igbavboa U, Wang L et al (2006) Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. NeuroMolecular Med 8:319\u2013328. https:\/\/doi.org\/10.1385\/nmm:8:3:319","journal-title":"NeuroMolecular Med"},{"key":"2232_CR59","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0305799101","volume":"101","author":"RG Cutler","year":"2004","unstructured":"Cutler RG, Kelly J, Storie K et al (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 101:2070\u20132075. https:\/\/doi.org\/10.1073\/pnas.0305799101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2232_CR60","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/325733a0","volume":"325","author":"J Kang","year":"1987","unstructured":"Kang J, Lemaire HG, Unterbeck A et al (1987) The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733\u2013736. https:\/\/doi.org\/10.1038\/325733a0","journal-title":"Nature"},{"key":"2232_CR61","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1073\/pnas.081612998","volume":"98","author":"E Kojro","year":"2001","unstructured":"Kojro E, Gimpl G, Lammich S et al (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the \u03b1-secretase ADAM 10. Proc Natl Acad Sci U S A 98:5815\u20135820. https:\/\/doi.org\/10.1073\/pnas.081612998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2232_CR62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/361260a0","volume":"361","author":"P Seubert","year":"1993","unstructured":"Seubert P, Oltersdorf T, Lee MG et al (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361:260\u2013263. https:\/\/doi.org\/10.1038\/361260a0","journal-title":"Nature"},{"key":"2232_CR63","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.bbalip.2010.03.007","volume":"1801","author":"KS Vetrivel","year":"2010","unstructured":"Vetrivel KS, Thinakaran G (2010) Membrane rafts in Alzheimer\u2019s disease beta-amyloid production. Biochim Biophys Acta 1801:860\u2013867. https:\/\/doi.org\/10.1016\/j.bbalip.2010.03.007","journal-title":"Biochim Biophys Acta"},{"key":"2232_CR64","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1096\/fj.10-168633","volume":"25","author":"C Marquer","year":"2011","unstructured":"Marquer C, Devauges V, Cossec J-C et al (2011) Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J Off Publ Fed Am Soc Exp Biol 25:1295\u20131305. https:\/\/doi.org\/10.1096\/fj.10-168633","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"2232_CR65","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1219988","volume":"336","author":"PJ Barrett","year":"2012","unstructured":"Barrett PJ, Song Y, Van Horn WD et al (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336:1168\u20131171. https:\/\/doi.org\/10.1126\/science.1219988","journal-title":"Science"},{"key":"2232_CR66","first-page":"912","volume":"321","author":"M Makarov","year":"2008","unstructured":"Makarov M, Grossard M (2008) Corrections and clarifications: efficient inhibition of the Alzheimer\u2019s disease \u03b2-secretase by membrane targeting. Science 321:912\u2013912","journal-title":"Science"},{"key":"2232_CR67","doi-asserted-by":"publisher","first-page":"363-375.e9","DOI":"10.1016\/j.stem.2018.12.013","volume":"24","author":"R van der Kant","year":"2019","unstructured":"van der Kant R, Langness VF, Herrera CM et al (2019) Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-\u03b2 in iPSC-derived Alzheimer\u2019s disease neurons. Cell Stem Cell 24:363-375.e9. https:\/\/doi.org\/10.1016\/j.stem.2018.12.013","journal-title":"Cell Stem Cell"},{"key":"2232_CR68","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41588-019-0495-7","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R et al (2019) Author correction: genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet 51:1423\u20131424. https:\/\/doi.org\/10.1038\/s41588-019-0495-7","journal-title":"Nat Genet"},{"key":"2232_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu C-C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol 9:106\u2013118. https:\/\/doi.org\/10.1038\/nrneurol.2012.263","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"2232_CR70","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet 41(10):1088\u20131093","journal-title":"Nat Genet"},{"key":"2232_CR71","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"J-C Lambert","year":"2009","unstructured":"Lambert J-C, Heath S, Even G et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet 41:1094\u20131099. https:\/\/doi.org\/10.1038\/ng.439","journal-title":"Nat Genet"},{"key":"2232_CR72","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder EH, Saunders AM, Risch NJ et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180\u2013184. https:\/\/doi.org\/10.1038\/ng0694-180","journal-title":"Nat Genet"},{"key":"2232_CR73","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0166-2236(94)90156-2","volume":"17","author":"J Poirier","year":"1994","unstructured":"Poirier J (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer\u2019s disease. Trends Neurosci 17:525\u2013530. https:\/\/doi.org\/10.1016\/0166-2236(94)90156-2","journal-title":"Trends Neurosci"},{"key":"2232_CR74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.biochi.2005.10.007","volume":"88","author":"A Rapp","year":"2006","unstructured":"Rapp A, Gmeiner B, H\u00fcttinger M (2006) Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88:473\u2013483. https:\/\/doi.org\/10.1016\/j.biochi.2005.10.007","journal-title":"Biochimie"},{"key":"2232_CR75","doi-asserted-by":"publisher","first-page":"29919","DOI":"10.1074\/jbc.M203934200","volume":"277","author":"J-S Gong","year":"2002","unstructured":"Gong J-S, Kobayashi M, Hayashi H et al (2002) Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 277:29919\u201329926. https:\/\/doi.org\/10.1074\/jbc.M203934200","journal-title":"J Biol Chem"},{"key":"2232_CR76","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1212\/wnl.46.6.1592","volume":"46","author":"RJ Ellis","year":"1996","unstructured":"Ellis RJ, Olichney JM, Thal LJ et al (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer\u2019s disease: the CERAD experience, part XV. Neurology 46:1592\u20131596. https:\/\/doi.org\/10.1212\/wnl.46.6.1592","journal-title":"Neurology"},{"key":"2232_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","volume":"34","author":"AS Fleisher","year":"2013","unstructured":"Fleisher AS, Chen K, Liu X et al (2013) Apolipoprotein E \u03b54 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 34:1\u201312. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.04.017","journal-title":"Neurobiol Aging"},{"key":"2232_CR78","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1523\/JNEUROSCI.4315-03.2004","volume":"24","author":"WJ Brecht","year":"2004","unstructured":"Brecht WJ, Harris FM, Chang S et al (2004) Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24:2527\u20132534. https:\/\/doi.org\/10.1523\/JNEUROSCI.4315-03.2004","journal-title":"J Neurosci"},{"key":"2232_CR79","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archgenpsychiatry.2010.78","volume":"67","author":"M Thambisetty","year":"2010","unstructured":"Thambisetty M, Simmons A, Velayudhan L et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67:739\u2013748. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.78","journal-title":"Arch Gen Psychiatry"},{"key":"2232_CR80","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00401-019-01994-1","volume":"138","author":"A De Roeck","year":"2019","unstructured":"De Roeck A, Van Broeckhoven C, Sleegers K (2019) The role of ABCA7 in Alzheimer\u2019s disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathol (Berl) 138:201\u2013220. https:\/\/doi.org\/10.1007\/s00401-019-01994-1","journal-title":"Acta Neuropathol (Berl)"},{"key":"2232_CR81","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R et al (2019) Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet 51:414\u2013430. https:\/\/doi.org\/10.1038\/s41588-019-0358-2","journal-title":"Nat Genet"},{"key":"2232_CR82","doi-asserted-by":"publisher","first-page":"837-854.e9","DOI":"10.1016\/j.neuron.2019.12.007","volume":"105","author":"AA Nugent","year":"2020","unstructured":"Nugent AA, Lin K, van Lengerich B et al (2020) TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron 105:837-854.e9. https:\/\/doi.org\/10.1016\/j.neuron.2019.12.007","journal-title":"Neuron"},{"key":"2232_CR83","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01725.x","volume":"260","author":"I Bj\u00f6rkhem","year":"2006","unstructured":"Bj\u00f6rkhem I (2006) Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 260:493\u2013508. https:\/\/doi.org\/10.1111\/j.1365-2796.2006.01725.x","journal-title":"J Intern Med"},{"key":"2232_CR84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fnagi.2015.00119","volume":"7","author":"P Gamba","year":"2015","unstructured":"Gamba P, Testa G, Gargiulo S et al (2015) Oxidized cholesterol as the driving force behind the development of Alzheimer\u2019s disease. Front Aging Neurosci 7:119. https:\/\/doi.org\/10.3389\/fnagi.2015.00119","journal-title":"Front Aging Neurosci"},{"key":"2232_CR85","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1194\/jlr.M034124","volume":"54","author":"Z Ali","year":"2013","unstructured":"Ali Z, Heverin M, Olin M et al (2013) On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1\u2212\/\u2212 mice. J Lipid Res 54:1033\u20131043. https:\/\/doi.org\/10.1194\/jlr.M034124","journal-title":"J Lipid Res"},{"key":"2232_CR86","doi-asserted-by":"publisher","first-page":"23712","DOI":"10.1074\/jbc.M114.556159","volume":"289","author":"AA Saeed","year":"2014","unstructured":"Saeed AA, Genov\u00e9 G, Li T et al (2014) Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. J Biol Chem 289:23712\u201323722. https:\/\/doi.org\/10.1074\/jbc.M114.556159","journal-title":"J Biol Chem"},{"issue":"Suppl 2","key":"2232_CR87","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1055\/s-2003-43053","volume":"36","author":"D L\u00fctjohann","year":"2003","unstructured":"L\u00fctjohann D, von Bergmann K (2003) 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36(Suppl 2):S102\u2013S106. https:\/\/doi.org\/10.1055\/s-2003-43053","journal-title":"Pharmacopsychiatry"},{"key":"2232_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068534","volume":"8","author":"S Maioli","year":"2013","unstructured":"Maioli S, B\u00e5vner A, Ali Z et al (2013) Is it possible to improve memory function by upregulation of the cholesterol 24S-hydroxylase (CYP46A1) in the brain? PLoS One 8:e68534. https:\/\/doi.org\/10.1371\/journal.pone.0068534","journal-title":"PLoS One"},{"key":"2232_CR89","doi-asserted-by":"publisher","first-page":"34674","DOI":"10.1074\/jbc.M402324200","volume":"279","author":"J Brown","year":"2004","unstructured":"Brown J, Theisler C, Silberman S et al (2004) Differential expression of cholesterol hydroxylases in Alzheimer\u2019s disease. J Biol Chem 279:34674\u201334681. https:\/\/doi.org\/10.1074\/jbc.M402324200","journal-title":"J Biol Chem"},{"key":"2232_CR90","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbrc.2007.05.033","volume":"359","author":"D Famer","year":"2007","unstructured":"Famer D, Meaney S, Mousavi M et al (2007) Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem Biophys Res Commun 359:46\u201350. https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.033","journal-title":"Biochem Biophys Res Commun"},{"key":"2232_CR91","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1172\/JCI16390","volume":"110","author":"K Simons","year":"2002","unstructured":"Simons K, Ehehalt R (2002) Cholesterol, lipid rafts, and disease. J Clin Invest 110:597\u2013603. https:\/\/doi.org\/10.1172\/JCI16390","journal-title":"J Clin Invest"},{"key":"2232_CR92","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1194\/jlr.M600529-JLR200","volume":"48","author":"S Meaney","year":"2007","unstructured":"Meaney S, Heverin M, Panzenboeck U et al (2007) Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res 48:944\u2013951. https:\/\/doi.org\/10.1194\/jlr.M600529-JLR200","journal-title":"J Lipid Res"},{"key":"2232_CR93","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1194\/jlr.M014548","volume":"52","author":"M Shafaati","year":"2011","unstructured":"Shafaati M, Marutle A, Pettersson H et al (2011) Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer\u2019s patients with the Swedish APP 670\/671 mutation. J Lipid Res 52:1004\u20131010. https:\/\/doi.org\/10.1194\/jlr.M014548","journal-title":"J Lipid Res"},{"key":"2232_CR94","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0306-4522(03)00438-x","volume":"121","author":"JLW Yau","year":"2003","unstructured":"Yau JLW, Rasmuson S, Andrew R et al (2003) Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer\u2019s disease. Neuroscience 121:307\u2013314. https:\/\/doi.org\/10.1016\/s0306-4522(03)00438-x","journal-title":"Neuroscience"},{"key":"2232_CR95","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1750-3639.2008.00174.x","volume":"19","author":"L Mateos","year":"2009","unstructured":"Mateos L, Akterin S, Gil-Bea F-J et al (2009) Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol Zurich Switz 19:69\u201380. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00174.x","journal-title":"Brain Pathol Zurich Switz"},{"key":"2232_CR96","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.mam.2009.02.001","volume":"30","author":"I Bj\u00f6rkhem","year":"2009","unstructured":"Bj\u00f6rkhem I, Cedazo-Minguez A, Leoni V, Meaney S (2009) Oxysterols and neurodegenerative diseases. Mol Asp Med 30:171\u2013179. https:\/\/doi.org\/10.1016\/j.mam.2009.02.001","journal-title":"Mol Asp Med"},{"key":"2232_CR97","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.20160534","volume":"214","author":"M-A-M Ismail","year":"2017","unstructured":"Ismail M-A-M, Mateos L, Maioli S et al (2017) 27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP\/GLUT4 system dysregulation. J Exp Med 214:699\u2013717. https:\/\/doi.org\/10.1084\/jem.20160534","journal-title":"J Exp Med"},{"key":"2232_CR98","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.bbr.2014.10.018","volume":"278","author":"M Heverin","year":"2015","unstructured":"Heverin M, Maioli S, Pham T et al (2015) 27-Hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice. Behav Brain Res 278:356\u2013359. https:\/\/doi.org\/10.1016\/j.bbr.2014.10.018","journal-title":"Behav Brain Res"},{"key":"2232_CR99","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3233\/JAD-2011-101512","volume":"24","author":"L Mateos","year":"2011","unstructured":"Mateos L, Ismail M-A-M, Gil-Bea F-J et al (2011) Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer\u2019s disease. J Alzheimers Dis JAD 24:669\u2013679. https:\/\/doi.org\/10.3233\/JAD-2011-101512","journal-title":"J Alzheimers Dis JAD"},{"key":"2232_CR100","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1586\/ern.11.36","volume":"11","author":"A Cedazo-M\u00ednguez","year":"2011","unstructured":"Cedazo-M\u00ednguez A, Ismail M-A-M, Mateos L (2011) Plasma cholesterol and risk for late-onset Alzheimer\u2019s disease. Expert Rev Neurother 11:495\u2013498. https:\/\/doi.org\/10.1586\/ern.11.36","journal-title":"Expert Rev Neurother"},{"key":"2232_CR101","doi-asserted-by":"publisher","first-page":"25574","DOI":"10.1074\/jbc.M111.236877","volume":"286","author":"L Mateos","year":"2011","unstructured":"Mateos L, Ismail M-A-M, Gil-Bea F-J et al (2011) Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism. J Biol Chem 286:25574\u201325585. https:\/\/doi.org\/10.1074\/jbc.M111.236877","journal-title":"J Biol Chem"},{"key":"2232_CR102","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3233\/JAD-2010-1298","volume":"19","author":"G Marwarha","year":"2010","unstructured":"Marwarha G, Dasari B, Prasanthi JRP et al (2010) Leptin reduces the accumulation of A\u03b2 and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis JAD 19:1007\u20131019. https:\/\/doi.org\/10.3233\/JAD-2010-1298","journal-title":"J Alzheimers Dis JAD"},{"key":"2232_CR103","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.081620098","volume":"98","author":"K Fassbender","year":"2001","unstructured":"Fassbender K, Simons M, Bergmann C et al (2001) Simvastatin strongly reduces levels of Alzheimer\u2019s disease \u03b2-amyloid peptides A\u03b242 and A\u03b240 in vitro and in vivo. Proc Natl Acad Sci U S A 98:5856\u20135861. https:\/\/doi.org\/10.1073\/pnas.081620098","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2232_CR104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MD.0000000000002143","volume":"94","author":"F-C Lin","year":"2015","unstructured":"Lin F-C, Chuang Y-S, Hsieh H-M et al (2015) Early statin use and the progression of Alzheimer disease. Medicine (Baltimore) 94:47. https:\/\/doi.org\/10.1097\/MD.0000000000002143","journal-title":"Medicine (Baltimore)"},{"key":"2232_CR105","first-page":"531","volume":"21","author":"H Kurinami","year":"2008","unstructured":"Kurinami H, Sato N, Shinohara M et al (2008) Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int J Mol Med 21:531\u2013537","journal-title":"Int J Mol Med"},{"key":"2232_CR106","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.21053","volume":"60","author":"L Li","year":"2006","unstructured":"Li L, Cao D, Kim H et al (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60:729\u2013739. https:\/\/doi.org\/10.1002\/ana.21053","journal-title":"Ann Neurol"},{"key":"2232_CR107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12031-002-0026-2","volume":"19","author":"SS Petanceska","year":"2002","unstructured":"Petanceska SS, DeRosa S, Olm V et al (2002) Statin therapy for Alzheimer\u2019s disease: will it work? J Mol Neurosci MN 19:155\u2013161. https:\/\/doi.org\/10.1007\/s12031-002-0026-2","journal-title":"J Mol Neurosci MN"},{"key":"2232_CR108","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1023\/b:nere.0000042217.90204.8d","volume":"29","author":"NB Chauhan","year":"2004","unstructured":"Chauhan NB, Siegel GJ, Feinstein DL (2004) Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res 29:1897\u20131911. https:\/\/doi.org\/10.1023\/b:nere.0000042217.90204.8d","journal-title":"Neurochem Res"},{"key":"2232_CR109","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0021-9150(01)00660-8","volume":"161","author":"D Paris","year":"2002","unstructured":"Paris D, Townsend KP, Humphrey J et al (2002) Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis 161:293\u2013299. https:\/\/doi.org\/10.1016\/s0021-9150(01)00660-8","journal-title":"Atherosclerosis"},{"key":"2232_CR110","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1083\/jcb.200404149","volume":"167","author":"J Abad-Rodriguez","year":"2004","unstructured":"Abad-Rodriguez J, Ledesma MD, Craessaerts K et al (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167:953\u2013960. https:\/\/doi.org\/10.1083\/jcb.200404149","journal-title":"J Cell Biol"},{"key":"2232_CR111","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ncb1001-905","volume":"3","author":"L Puglielli","year":"2001","unstructured":"Puglielli L, Konopka G, Pack-Chung E et al (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3:905\u2013912. https:\/\/doi.org\/10.1038\/ncb1001-905","journal-title":"Nat Cell Biol"},{"key":"2232_CR112","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neuron.2004.08.043","volume":"44","author":"B Hutter-Paier","year":"2004","unstructured":"Hutter-Paier B, Huttunen HJ, Puglielli L et al (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer\u2019s disease. Neuron 44:227\u2013238. https:\/\/doi.org\/10.1016\/j.neuron.2004.08.043","journal-title":"Neuron"},{"key":"2232_CR113","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","volume":"57","author":"B Wolozin","year":"2000","unstructured":"Wolozin B, Kellman W, Ruosseau P et al (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439\u20131443. https:\/\/doi.org\/10.1001\/archneur.57.10.1439","journal-title":"Arch Neurol"},{"key":"2232_CR114","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1741-7015-5-20","volume":"5","author":"B Wolozin","year":"2007","unstructured":"Wolozin B, Wang SW, Li N-C et al (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease. BMC Med 5:20. https:\/\/doi.org\/10.1186\/1741-7015-5-20","journal-title":"BMC Med"},{"key":"2232_CR115","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.2008.150433","volume":"80","author":"MDM Haag","year":"2009","unstructured":"Haag MDM, Hofman A, Koudstaal PJ et al (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80:13\u201317. https:\/\/doi.org\/10.1136\/jnnp.2008.150433","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2232_CR116","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"HH Feldman","year":"2010","unstructured":"Feldman HH, Doody RS, Kivipelto M et al (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74:956\u2013964. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d6476a","journal-title":"Neurology"},{"key":"2232_CR117","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archneur.62.5.753","volume":"62","author":"DL Sparks","year":"2005","unstructured":"Sparks DL, Sabbagh MN, Connor DJ et al (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62:753\u2013757. https:\/\/doi.org\/10.1001\/archneur.62.5.753","journal-title":"Arch Neurol"},{"key":"2232_CR118","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/S1461145701002310","volume":"4","author":"LT Friedhoff","year":"2001","unstructured":"Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD (2001) Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol 4:127\u2013130. https:\/\/doi.org\/10.1017\/S1461145701002310","journal-title":"Int J Neuropsychopharmacol"},{"key":"2232_CR119","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archneur.59.2.223","volume":"59","author":"K Rockwood","year":"2002","unstructured":"Rockwood K, Kirkland S, Hogan DB et al (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59:223\u2013227. https:\/\/doi.org\/10.1001\/archneur.59.2.223","journal-title":"Arch Neurol"},{"key":"2232_CR120","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/archneur.62.7.1047","volume":"62","author":"TD Rea","year":"2005","unstructured":"Rea TD, Breitner JC, Psaty BM et al (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62:1047\u20131051. https:\/\/doi.org\/10.1001\/archneur.62.7.1047","journal-title":"Arch Neurol"},{"key":"2232_CR121","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1212\/01.wnl.0000286942.14552.51","volume":"70","author":"AD Wahner","year":"2008","unstructured":"Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2008) Statin use and the risk of Parkinson\u2019s disease. Neurology 70:1418\u20131422. https:\/\/doi.org\/10.1212\/01.wnl.0000286942.14552.51","journal-title":"Neurology"},{"key":"2232_CR122","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"O-B Tysnes","year":"2017","unstructured":"Tysnes O-B, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm Vienna Austria 1996 124:901\u2013905. https:\/\/doi.org\/10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"2232_CR123","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet Lond Engl 386:896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet Lond Engl"},{"key":"2232_CR124","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-017-0077-5","volume":"6","author":"P Sweeney","year":"2017","unstructured":"Sweeney P, Park H et al (2017) Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener 6:6. https:\/\/doi.org\/10.1186\/s40035-017-0077-5","journal-title":"Transl Neurodegener"},{"key":"2232_CR125","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10571-018-0587-4","volume":"38","author":"A Karimi-Moghadam","year":"2018","unstructured":"Karimi-Moghadam A, Charsouei S, Bell B, Jabalameli MR (2018) Parkinson disease from Mendelian forms to genetic susceptibility: new molecular insights into the neurodegeneration process. Cell Mol Neurobiol 38:1153\u20131178. https:\/\/doi.org\/10.1007\/s10571-018-0587-4","journal-title":"Cell Mol Neurobiol"},{"key":"2232_CR126","doi-asserted-by":"publisher","unstructured":"Wei Q, Wang H, Tian Y et al (2013) Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson\u2019s disease patients. PLoS ONE 8. https:\/\/doi.org\/10.1371\/journal.pone.0075743","DOI":"10.1371\/journal.pone.0075743"},{"key":"2232_CR127","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mds.21290","volume":"22","author":"X Huang","year":"2007","unstructured":"Huang X, Chen H, Miller WC et al (2007) Lower low density lipid cholesterol levels are associated with Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc 22:377\u2013381. https:\/\/doi.org\/10.1002\/mds.21290","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2232_CR128","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/mds.26290","volume":"30","author":"CR Swanson","year":"2015","unstructured":"Swanson CR, Berlyand Y, Xie SX et al (2015) Plasma ApoA1 associates with age at onset and motor severity in early Parkinson disease patients. Mov Disord Off J Mov Disord Soc 30:1648\u20131656. https:\/\/doi.org\/10.1002\/mds.26290","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2232_CR129","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.23872","volume":"74","author":"JK Qiang","year":"2013","unstructured":"Qiang JK, Wong YC, Siderowf A et al (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson\u2019s disease. Ann Neurol 74:119\u2013127. https:\/\/doi.org\/10.1002\/ana.23872","journal-title":"Ann Neurol"},{"key":"2232_CR130","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0197-4580(03)00005-8","volume":"24","author":"CE Teunissen","year":"2003","unstructured":"Teunissen CE, L\u00fctjohann D, Bergmann KV et al (2003) Combination of serum markers related to several mechanisms in Alzheimer\u2019s disease. Neurobiol Aging 24:893\u2013902. https:\/\/doi.org\/10.1016\/S0197-4580(03)00005-8","journal-title":"Neurobiol Aging"},{"key":"2232_CR131","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jns.2004.05.007","volume":"223","author":"M Sohmiya","year":"2004","unstructured":"Sohmiya M, Tanaka M, Tak NW et al (2004) Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson\u2019s disease. J Neurol Sci 223:161\u2013166. https:\/\/doi.org\/10.1016\/j.jns.2004.05.007","journal-title":"J Neurol Sci"},{"key":"2232_CR132","doi-asserted-by":"publisher","unstructured":"de Lau LML, Koudstaal PJ, Albert H, Breteler MMB (2006) Serum cholesterol levels and the risk of Parkinson\u2019s disease. Am J Epidemiol 10. https:\/\/doi.org\/10.1093\/aje\/kwj283","DOI":"10.1093\/aje\/kwj283"},{"key":"2232_CR133","doi-asserted-by":"publisher","unstructured":"Rozani V, Gurevich T, Giladi N et al (2018) Higher serum cholesterol and decreased Parkinson\u2019s disease risk: a statin-free cohort study. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27413","DOI":"10.1002\/mds.27413"},{"key":"2232_CR134","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1212\/01.wnl.0000312511.62699.a8","volume":"70","author":"G Hu","year":"2008","unstructured":"Hu G, Antikainen R, Jousilahti P et al (2008) Total cholesterol and the risk of Parkinson disease. Neurology 70:1972\u20131979. https:\/\/doi.org\/10.1212\/01.wnl.0000312511.62699.a8","journal-title":"Neurology"},{"key":"2232_CR135","doi-asserted-by":"publisher","first-page":"836962","DOI":"10.4061\/2010\/836962","volume":"2010","author":"G Hu","year":"2009","unstructured":"Hu G (2009) Total cholesterol and the risk of Parkinson\u2019s disease: a review for some new findings. Park Dis 2010:836962. https:\/\/doi.org\/10.4061\/2010\/836962","journal-title":"Park Dis"},{"key":"2232_CR136","doi-asserted-by":"publisher","unstructured":"Peter S et al (2002) Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer\u2019s disease compared to healthy controls. Neurosci Lett. https:\/\/doi.org\/10.1016\/S0304-3940(02)00164-7","DOI":"10.1016\/S0304-3940(02)00164-7"},{"key":"2232_CR137","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/ars.2008.2179","volume":"11","author":"C-YJ Lee","year":"2009","unstructured":"Lee C-YJ, Seet RCS, Huang SH et al (2009) Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson\u2019s disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid Redox Signal 11:407\u2013420. https:\/\/doi.org\/10.1089\/ars.2008.2179","journal-title":"Antioxid Redox Signal"},{"key":"2232_CR138","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neulet.2013.09.003","volume":"555","author":"I Bj\u00f6rkhem","year":"2013","unstructured":"Bj\u00f6rkhem I, L\u00f6vgren-Sandblom A, Leoni V et al (2013) Oxysterols and Parkinson\u2019s disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett 555:102\u2013105. https:\/\/doi.org\/10.1016\/j.neulet.2013.09.003","journal-title":"Neurosci Lett"},{"key":"2232_CR139","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1212\/01.wnl.0000130159.28215.6a","volume":"62","author":"X Huang","year":"2004","unstructured":"Huang X, Chen PC, Poole C (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62:2198\u20132202. https:\/\/doi.org\/10.1212\/01.wnl.0000130159.28215.6a","journal-title":"Neurology"},{"key":"2232_CR140","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s004010050824","volume":"95","author":"K Wakabayashi","year":"1998","unstructured":"Wakabayashi K, Kakita A, Hayashi S et al (1998) Apolipoprotein E epsilon4 allele and progression of cortical Lewy body pathology in Parkinson\u2019s disease. Acta Neuropathol (Berl) 95:450\u2013454. https:\/\/doi.org\/10.1007\/s004010050824","journal-title":"Acta Neuropathol (Berl)"},{"key":"2232_CR141","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/archneur.63.2.189","volume":"63","author":"X Huang","year":"2006","unstructured":"Huang X, Chen P, Kaufer DI et al (2006) Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 63:189\u2013193. https:\/\/doi.org\/10.1001\/archneur.63.2.189","journal-title":"Arch Neurol"},{"key":"2232_CR142","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00415-009-0119-8","volume":"256","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray CH, Goris A, Saiki M et al (2009) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson\u2019s disease. J Neurol 256:493\u2013498. https:\/\/doi.org\/10.1007\/s00415-009-0119-8","journal-title":"J Neurol"},{"key":"2232_CR143","doi-asserted-by":"publisher","first-page":"2106.e1-2106.e6","DOI":"10.1016\/j.neurobiolaging.2011.05.016","volume":"32","author":"J Gao","year":"2011","unstructured":"Gao J, Huang X, Park Y et al (2011) Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging 32:2106.e1-2106.e6. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.05.016","journal-title":"Neurobiol Aging"},{"key":"2232_CR144","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.nbd.2012.02.002","volume":"46","author":"M Federoff","year":"2012","unstructured":"Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB (2012) A large study reveals no association between APOE and Parkinson\u2019s disease. Neurobiol Dis 46:389\u2013392. https:\/\/doi.org\/10.1016\/j.nbd.2012.02.002","journal-title":"Neurobiol Dis"},{"key":"2232_CR145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exger.2014.09.013","volume":"68","author":"G Marwarha","year":"2015","unstructured":"Marwarha G, Ghribi O (2015) Does the oxysterol 27-hydroxycholesterol underlie Alzheimer\u2019s disease-Parkinson\u2019s disease overlap? Exp Gerontol 68:13\u201318. https:\/\/doi.org\/10.1016\/j.exger.2014.09.013","journal-title":"Exp Gerontol"},{"key":"2232_CR146","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/mds.27681","volume":"34","author":"S-M Jeong","year":"2019","unstructured":"Jeong S-M, Jang W, Shin DW (2019) Association of statin use with Parkinson\u2019s disease: dose-response relationship. Mov Disord Off J Mov Disord Soc 34:1014\u20131021. https:\/\/doi.org\/10.1002\/mds.27681","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2232_CR147","first-page":"286","volume":"51","author":"T Kimura","year":"2002","unstructured":"Kimura T, Hasegawa M, Takano O (2002) The effect of dopamine on serum lipid concentration after propofol administration. Masui 51:286\u2013288","journal-title":"Masui"},{"key":"2232_CR148","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1007\/s11064-013-1110-4","volume":"38","author":"J de Oliveira","year":"2013","unstructured":"de Oliveira J, Moreira ELG, Mancini G et al (2013) Diphenyl diselenide prevents cortico-cerebral mitochondrial dysfunction and oxidative stress induced by hypercholesterolemia in LDL receptor knockout mice. Neurochem Res 38:2028\u20132036. https:\/\/doi.org\/10.1007\/s11064-013-1110-4","journal-title":"Neurochem Res"},{"key":"2232_CR149","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1471-4159.2008.05415.x","volume":"106","author":"L Thirumangalakudi","year":"2008","unstructured":"Thirumangalakudi L, Prakasam A, Zhang R et al (2008) High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 106:475\u2013485. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05415.x","journal-title":"J Neurochem"},{"key":"2232_CR150","doi-asserted-by":"publisher","first-page":"R1082","DOI":"10.1152\/ajpregu.00449.2010","volume":"299","author":"JK Morris","year":"2010","unstructured":"Morris JK, Bomhoff GL, Stanford JA, Geiger PC (2010) Neurodegeneration in an animal model of Parkinson\u2019s disease is exacerbated by a high-fat diet. Am J Physiol - Regul Integr Comp Physiol 299:R1082\u2013R1090. https:\/\/doi.org\/10.1152\/ajpregu.00449.2010","journal-title":"Am J Physiol - Regul Integr Comp Physiol"},{"key":"2232_CR151","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40035-019-0172-x","volume":"8","author":"NP Visanji","year":"2019","unstructured":"Visanji NP, Lang AE, Kovacs GG (2019) Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Transl Neurodegener 8:28. https:\/\/doi.org\/10.1186\/s40035-019-0172-x","journal-title":"Transl Neurodegener"},{"key":"2232_CR152","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2119\/molmed.2011.00119","volume":"17","author":"N Fabelo","year":"2011","unstructured":"Fabelo N, Mart\u00edn V, Santpere G et al (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson\u2019s disease and incidental Parkinson\u2019s disease. Mol Med 17:1107\u20131118. https:\/\/doi.org\/10.2119\/molmed.2011.00119","journal-title":"Mol Med"},{"key":"2232_CR153","doi-asserted-by":"publisher","unstructured":"Ida E, Nath S et al (2017) Impact of high cholesterol in a Parkinson\u2019s disease model: prevention of lysosomal leakage versus stimulation of \u03b1-synuclein aggregation. Eur J Cell Biol. https:\/\/doi.org\/10.1016\/j.ejcb.2017.01.002","DOI":"10.1016\/j.ejcb.2017.01.002"},{"key":"2232_CR154","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1161\/01.atv.15.11.1812","volume":"15","author":"CA Abbott","year":"1995","unstructured":"Abbott CA, Mackness MI, Kumar S et al (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812\u20131818. https:\/\/doi.org\/10.1161\/01.atv.15.11.1812","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2232_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1326-4-1","volume":"4","author":"JR Prasanthi","year":"2009","unstructured":"Prasanthi JR, Huls A, Thomasson S et al (2009) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on \u03b2-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegener 4:1. https:\/\/doi.org\/10.1186\/1750-1326-4-1","journal-title":"Mol Neurodegener"},{"key":"2232_CR156","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1471-4159.2004.02373.x","volume":"89","author":"Z Balazs","year":"2004","unstructured":"Balazs Z, Panzenboeck U, Hammer A et al (2004) Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 89:939\u2013950. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02373.x","journal-title":"J Neurochem"},{"key":"2232_CR157","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12031-017-0967-0","volume":"63","author":"FN Emamzadeh","year":"2017","unstructured":"Emamzadeh FN, Allsop D (2017) \u03b1-Synuclein interacts with lipoproteins in plasma. J Mol Neurosci 63:165. https:\/\/doi.org\/10.1007\/s12031-017-0967-0","journal-title":"J Mol Neurosci"},{"key":"2232_CR158","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2017","unstructured":"Shahmoradian SH, Genoud C, Graffmeyer A et al (2017) Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci 22:1099\u20131109. https:\/\/doi.org\/10.1038\/s41593-019-0423-2","journal-title":"Nat Neurosci"},{"key":"2232_CR159","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1093\/brain\/awh584","volume":"128","author":"GM Halliday","year":"2005","unstructured":"Halliday GM, Ophof A, Broe M et al (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson\u2019s disease. Brain J Neurol 128:2654\u20132664. https:\/\/doi.org\/10.1093\/brain\/awh584","journal-title":"Brain J Neurol"},{"key":"2232_CR160","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1523\/JNEUROSCI.2898-12.2013","volume":"33","author":"D Boassa","year":"2013","unstructured":"Boassa D, Berlanga ML, Yang MA et al (2013) Mapping the subcellular distribution of \u03b1-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson\u2019s disease pathogenesis. J Neurosci 33:2605\u20132615. https:\/\/doi.org\/10.1523\/JNEUROSCI.2898-12.2013","journal-title":"J Neurosci"},{"issue":"30","key":"2232_CR161","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.0535-12.2012","volume":"32","author":"D Scott","year":"2012","unstructured":"Scott D, Roy S (2012) \u03b1-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 32(30):10129\u201310135. https:\/\/doi.org\/10.1523\/JNEUROSCI.0535-12.2012","journal-title":"J Neurosci"},{"key":"2232_CR162","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/neup.12204","volume":"35","author":"K Nakamura","year":"2015","unstructured":"Nakamura K, Mori F, Tanji K et al (2015) Isopentenyl diphosphate isomerase, a cholesterol synthesizing enzyme, is localized in Lewy bodies. Neuropathol Off J Jpn Soc Neuropathol 35:432\u2013440. https:\/\/doi.org\/10.1111\/neup.12204","journal-title":"Neuropathol Off J Jpn Soc Neuropathol"},{"key":"2232_CR163","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","volume":"105","author":"P Baron","year":"2008","unstructured":"Baron P, Crews L, Koob AO et al (2008) Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson\u2019s disease. J Neurochem 105:1656\u20131667. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05254.x","journal-title":"J Neurochem"},{"key":"2232_CR164","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/1531-8249(199905)45:5<611::aid-ana9>3.0.co;2-x","volume":"45","author":"R Kr\u00fcger","year":"1999","unstructured":"Kr\u00fcger R, Vieira-Saecker AM, Kuhn W et al (1999) Increased susceptibility to sporadic Parkinson\u2019s disease by a certain combined alpha-synuclein\/apolipoprotein E genotype. Ann Neurol 45:611\u2013617. https:\/\/doi.org\/10.1002\/1531-8249(199905)45:5<611::aid-ana9>3.0.co;2-x","journal-title":"Ann Neurol"},{"key":"2232_CR165","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.bbamem.2011.06.017","volume":"1808","author":"J Fantini","year":"2011","unstructured":"Fantini J, Carlus D, Yahi N (2011) The fusogenic tilted peptide (67-78) of \u03b1-synuclein is a cholesterol binding domain. Biochim Biophys Acta 1808:2343\u20132351. https:\/\/doi.org\/10.1016\/j.bbamem.2011.06.017","journal-title":"Biochim Biophys Acta"},{"issue":"10","key":"2232_CR166","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/molecules22101769","volume":"22","author":"J-HT Hsiao","year":"2017","unstructured":"Hsiao J-HT, Halliday GM et al (2017) \u03b1-Synuclein regulates neuronal cholesterol efflux. Molecules 22(10):1769","journal-title":"Molecules"},{"key":"2232_CR167","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.peptides.2014.09.018","volume":"62","author":"Y-T Sui","year":"2014","unstructured":"Sui Y-T, Bullock KM, Erickson MA et al (2014) Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides 62:197\u2013202. https:\/\/doi.org\/10.1016\/j.peptides.2014.09.018","journal-title":"Peptides"},{"issue":"1","key":"2232_CR168","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1471-4159.2006.04348.x","volume":"110","author":"G Barcel\u00f3-Coblijn","year":"2007","unstructured":"Barcel\u00f3-Coblijn G et al (2007) Brain neutral lipids mass is increased in \u03b1-synuclein gene-ablated mice. J Neurochem 110(1):132\u2013141. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04348.x","journal-title":"J Neurochem"},{"key":"2232_CR169","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1016\/j.febslet.2015.08.013","volume":"589","author":"A van Maarschalkerweerd","year":"2015","unstructured":"van Maarschalkerweerd A, Vetri V, Vestergaard B (2015) Cholesterol facilitates interactions between \u03b1-synuclein oligomers and charge-neutral membranes. FEBS Lett 589:2661\u20132667. https:\/\/doi.org\/10.1016\/j.febslet.2015.08.013","journal-title":"FEBS Lett"},{"key":"2232_CR170","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.neulet.2016.02.042","volume":"618","author":"FN Emamzadeh","year":"2016","unstructured":"Emamzadeh FN, Aojula H, McHugh PC, Allsop D (2016) Effects of different isoforms of apoE on aggregation of the \u03b1-synuclein protein implicated in Parkinson\u2019s disease. Neurosci Lett 618:146\u2013151. https:\/\/doi.org\/10.1016\/j.neulet.2016.02.042","journal-title":"Neurosci Lett"},{"issue":"1","key":"2232_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005907","volume":"14","author":"T Zeppelin","year":"2018","unstructured":"Zeppelin T, Ladefoged LK, Sinning S et al (2018) A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition. PLoS Comput Biol 14(1):e1005907. https:\/\/doi.org\/10.1371\/journal.pcbi.1005907","journal-title":"PLoS Comput Biol"},{"key":"2232_CR172","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1471-4159.2012.07813.x","volume":"122","author":"A Or\u0142owski","year":"2012","unstructured":"Or\u0142owski A, Grzybek M, Bunker A et al (2012) Strong preferences of dopamine and l-dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism. J Neurochem 122:681\u2013690. https:\/\/doi.org\/10.1111\/j.1471-4159.2012.07813.x","journal-title":"J Neurochem"},{"key":"2232_CR173","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/jnc.12007","volume":"123","author":"KT Jones","year":"2012","unstructured":"Jones KT, Zhen J, Reith MEA (2012) Importance of cholesterol in dopamine transporter function. J Neurochem 123:700\u2013715. https:\/\/doi.org\/10.1111\/jnc.12007","journal-title":"J Neurochem"},{"key":"2232_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2019.04.056","volume":"410","author":"W Zhuge","year":"2019","unstructured":"Zhuge W, Wen F, Ni Z et al (2019) Dopamine burden triggers cholesterol overload following disruption of synaptogenesis in minimal hepatic encephalopathy. Neuroscience 410:1\u201315. https:\/\/doi.org\/10.1016\/j.neuroscience.2019.04.056","journal-title":"Neuroscience"},{"key":"2232_CR175","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000481551","volume":"24","author":"A Raju","year":"2017","unstructured":"Raju A, Jaisankar P, Borah A, Mohanakumar KP (2017) 1-Methyl-4-phenylpyridinium-induced death of differentiated SH-SY5Y neurons is potentiated by cholesterol. Ann Neurosci 24:243\u2013251. https:\/\/doi.org\/10.1159\/000481551","journal-title":"Ann Neurosci"},{"key":"2232_CR176","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0006-8993(98)01274-8","volume":"818","author":"H K\u00f6lsch","year":"1999","unstructured":"K\u00f6lsch H, L\u00fctjohann D, Tulke A et al (1999) The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res 818:171\u2013175. https:\/\/doi.org\/10.1016\/s0006-8993(98)01274-8","journal-title":"Brain Res"},{"key":"2232_CR177","doi-asserted-by":"publisher","first-page":"24666","DOI":"10.1074\/jbc.M111.236273","volume":"286","author":"K Yamanaka","year":"2011","unstructured":"Yamanaka K, Saito Y, Yamamori T et al (2011) 24(S)-hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis. J Biol Chem 286:24666\u201324673. https:\/\/doi.org\/10.1074\/jbc.M111.236273","journal-title":"J Biol Chem"},{"key":"2232_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.524","volume":"5","author":"K Yamanaka","year":"2014","unstructured":"Yamanaka K, Urano Y, Takabe W et al (2014) Induction of apoptosis and necroptosis by 24(S)-hydroxycholesterol is dependent on activity of acyl-CoA:cholesterol acyltransferase 1. Cell Death Dis 5:e990. https:\/\/doi.org\/10.1038\/cddis.2013.524","journal-title":"Cell Death Dis"},{"key":"2232_CR179","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/WNR.0b013e32831578b2","volume":"19","author":"D Cheng","year":"2008","unstructured":"Cheng D, Kim WS, Garner B (2008) Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport 19:1685\u20131689. https:\/\/doi.org\/10.1097\/WNR.0b013e32831578b2","journal-title":"Neuroreport"},{"issue":"1","key":"2232_CR180","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12868-018-0420-5","volume":"19","author":"J Schommer","year":"2018","unstructured":"Schommer J, Marwarha G, Schommer T et al (2018) 27-Hydroxycholesterol increases \u03b1-synuclein protein levels through proteasomal inhibition in human dopaminergic neurons. BMC Neurosci 19(1):17. https:\/\/doi.org\/10.1186\/s12868-018-0420-5","journal-title":"BMC Neurosci"},{"key":"2232_CR181","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/j.1471-4159.2008.05736.x","volume":"107","author":"G Marwarha","year":"2008","unstructured":"Marwarha G, Rhen T, Schommer T, Ghribi O (2008) The oxysterol 27-hydroxycholesterol regulates \u03b1-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors-relevance to Parkinson\u2019s disease. J Neurochem 107:1722\u20131729. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05736.x","journal-title":"J Neurochem"},{"key":"2232_CR182","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nchembio782","volume":"2","author":"DA Bosco","year":"2006","unstructured":"Bosco DA, Fowler DM, Zhang Q et al (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2:249\u2013253. https:\/\/doi.org\/10.1038\/nchembio782","journal-title":"Nat Chem Biol"},{"key":"2232_CR183","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1021\/ar0500766","volume":"39","author":"J Bieschke","year":"2006","unstructured":"Bieschke J, Zhang Q, Bosco DA et al (2006) Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res 39:611\u2013619. https:\/\/doi.org\/10.1021\/ar0500766","journal-title":"Acc Chem Res"},{"key":"2232_CR184","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jnr.23329","volume":"92","author":"J Yan","year":"2014","unstructured":"Yan J, Sun J, Huang L et al (2014) Simvastatin prevents neuroinflammation by inhibiting N-methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. J Neurosci Res 92:634\u2013640. https:\/\/doi.org\/10.1002\/jnr.23329","journal-title":"J Neurosci Res"},{"key":"2232_CR185","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1371\/journal.pone.0020945","volume":"6","author":"J Yan","year":"2011","unstructured":"Yan J, Xu Y, Zhu C et al (2011) Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One 6:6. https:\/\/doi.org\/10.1371\/journal.pone.0020945","journal-title":"PLoS One"},{"key":"2232_CR186","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cns.12053","volume":"19","author":"Y Xu","year":"2012","unstructured":"Xu Y, Long L, Yan J et al (2012) Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K\/AKT\/caspase 3 pathway and anti-inflammatory responses. CNS Neurosci Ther 19:170\u2013177. https:\/\/doi.org\/10.1111\/cns.12053","journal-title":"CNS Neurosci Ther"},{"key":"2232_CR187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","volume":"1037","author":"ML Selley","year":"2005","unstructured":"Selley ML (2005) Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 1037:1\u20136. https:\/\/doi.org\/10.1016\/j.brainres.2004.02.083","journal-title":"Brain Res"},{"key":"2232_CR188","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2012.06.050","volume":"1471","author":"A Kumar","year":"2012","unstructured":"Kumar A, Sharma N, Gupta A et al (2012) Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res 1471:13\u201322. https:\/\/doi.org\/10.1016\/j.brainres.2012.06.050","journal-title":"Brain Res"},{"key":"2232_CR189","first-page":"3313","volume":"7","author":"J-Q Yan","year":"2014","unstructured":"Yan J-Q, Ma Y-J, Sun J-C et al (2014) Neuroprotective effect of lovastatin by inhibiting NMDA receptor1 in 6-hydroxydopamine treated PC12 cells. Int J Clin Exp Med 7:3313\u20133319","journal-title":"Int J Clin Exp Med"},{"key":"2232_CR190","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","volume":"221","author":"AO Koob","year":"2010","unstructured":"Koob AO, Ubhi K, Paulsson JF et al (2010) Lovastatin ameliorates \u03b1-synuclein accumulation and oxidation in transgenic mouse models of \u03b1-synucleinopathies. Exp Neurol 221:267\u2013274. https:\/\/doi.org\/10.1016\/j.expneurol.2009.11.015","journal-title":"Exp Neurol"},{"key":"2232_CR191","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1212\/WNL.0b013e31829d873c","volume":"81","author":"Y-C Lee","year":"2013","unstructured":"Lee Y-C, Lin C-H, Wu R-M et al (2013) Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 81:410\u2013416. https:\/\/doi.org\/10.1212\/WNL.0b013e31829d873c","journal-title":"Neurology"},{"key":"2232_CR192","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mds.26152","volume":"30","author":"X Huang","year":"2015","unstructured":"Huang X, Alonso A, Guo X et al (2015) Statins, plasma cholesterol and risk of Parkinson\u2019s disease: a prospective study. Mov Disord Off J Mov Disord Soc 30:552\u2013559. https:\/\/doi.org\/10.1002\/mds.26152","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2232_CR193","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mds.27006","volume":"32","author":"G Liu","year":"2017","unstructured":"Liu G, Sterling NW, Kong L et al (2017) Statins may facilitate Parkinson\u2019s disease: insight gained from a large, national claims database. Mov Disord Off J Mov Disord Soc 32:913\u2013917. https:\/\/doi.org\/10.1002\/mds.27006","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"2232_CR194","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175054","volume":"12","author":"V Rozani","year":"2017","unstructured":"Rozani V, Giladi N, El-Ad B et al (2017) Statin adherence and the risk of Parkinson\u2019s disease: a population-based cohort study. PLoS One 12:e0175054. https:\/\/doi.org\/10.1371\/journal.pone.0175054","journal-title":"PLoS One"},{"key":"2232_CR195","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014852","volume":"98","author":"J Yan","year":"2019","unstructured":"Yan J, Qiao L, Tian J et al (2019) Effect of statins on Parkinson\u2019s disease: a systematic review and meta-analysis. Medicine (Baltimore) 98:e14852. https:\/\/doi.org\/10.1097\/MD.0000000000014852","journal-title":"Medicine (Baltimore)"},{"key":"2232_CR196","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1371\/journal.pone.0152564","volume":"11","author":"S Bai","year":"2016","unstructured":"Bai S, Song Y, Huang X et al (2016) Statin use and the risk of Parkinson\u2019s disease: an updated meta-analysis. PLoS One 11:3. https:\/\/doi.org\/10.1371\/journal.pone.0152564","journal-title":"PLoS One"},{"key":"2232_CR197","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbr.2016.04.046","volume":"309","author":"Z Sheng","year":"2016","unstructured":"Sheng Z, Jia X, Kang M (2016) Statin use and risk of Parkinson\u2019s disease: a meta-analysis. Behav Brain Res 309:29\u201334. https:\/\/doi.org\/10.1016\/j.bbr.2016.04.046","journal-title":"Behav Brain Res"},{"key":"2232_CR198","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JAD-2010-101179","volume":"23","author":"S Sierra","year":"2011","unstructured":"Sierra S, Ramos MC, Molina P et al (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis JAD 23:307\u2013318. https:\/\/doi.org\/10.3233\/JAD-2010-101179","journal-title":"J Alzheimers Dis JAD"},{"key":"2232_CR199","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","volume":"88","author":"PJ van der Most","year":"2009","unstructured":"van der Most PJ, Dolga AM, Nijholt IM et al (2009) Statins: mechanisms of neuroprotection. Prog Neurobiol 88:64\u201375. https:\/\/doi.org\/10.1016\/j.pneurobio.2009.02.002","journal-title":"Prog Neurobiol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02232-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-020-02232-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-02232-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T13:15:35Z","timestamp":1617369335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-020-02232-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":199,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-02232-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}